drug_type
RELEVANT_DRUG
intervention_type
Genetically modified cellular therapy (CAR T)
drug_description
Autologous CAR T cells targeting CD19 on B-lineage cells (naive, memory, some plasmablasts) to deplete autoreactive B cells and reduce antigen presentation and autoantibody production.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically modified to express a chimeric antigen receptor targeting CD19; upon binding CD19 on B-lineage cells (naive, memory, some plasmablasts), CAR signaling activates cytotoxic pathways (perforin/granzyme, death receptors) to deplete B cells, thereby reducing antigen presentation and autoantibody production and helping reset dysregulated humoral immunity.
drug_name
CD19 CAR-T cells
nct_id_drug_ref
NCT06428188